Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant hepatitis E vaccine in Child-Pugh A/B cirrhosis patients
ChiCTR2000036720Phase 4Not yet recruiting
- Sponsor
- Shanghai Public Health Clinical Center
- Start
- Oct 2020
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of HEV 239 in hepatitis E (HEV), sponsored by Shanghai Public Health Clinical Center. Primary endpoints: HEV-IgG antibody response and Hepatitis E infection occurrence. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
HEV 239
03
Conditions
hepatitis E (HEV)
Beyond the preview
Go deeper on ChiCTR2000036720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036720.